First, we tested the stability of K17 in KCs upon treatment with the protein synthesis inhibitor cycloheximide (CHX) in control, Pso Mix-treated, and ENO1 siRNA-treated HaCaT cells. This evidence concerns the gene ENO1 and dry eye syndrome.